TuHURA Biosciences gets FDA IND clearance for TBS-2025 study
TuHURA Biosciences said the FDA issued a “Study May Proceed” notice and IND clearance for evaluating its TBS-2025 antibody in molecularly defined subsets of AML and other blood-related cancers.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.